Maintained anxiolytic effects of cannabidiol after treatment discontinuation in healthcare workers during the COVID-19 pandemic

• Главные авторы: José Diogo S. Souza (Автор), Antonio W. Zuardi (Автор), Francisco S. Guimarães (Автор), Flávia de Lima Osório (Автор), Sonia Regina Loureiro (Автор), Alline Cristina Campos (Автор), Jaime E. C. Hallak (Автор), Rafael G. Dos Santos (Автор), Isabella Lara Machado Silveira (Автор), Karina Pereira-Lima (Автор), Julia Cozar Pacheco (Автор), Juliana Mayumi Ushirohira (Автор), Rafael Rinaldi Ferreira (Автор), Karla Cristinne Mancini Costa (Автор), Davi Silveira Scomparin (Автор), Franciele Franco Scarante (Автор), Isabela Pires- (Автор), Raphael Mechoulam (Автор), Flávio Kapczinski (Автор), Benedito A. L. Fonseca (Автор), Danillo L. A. Esposito (Автор), Maristela Haddad Andraus (Автор), José Alexandre S. Crippa (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Objective: To assess whether the effects of oral administration of 300 mg of Cannabidiol (CBD) for 28 days on mental health are maintained for a period after the medication discontinuation.Methods: This is a 3-month follow-up observational and clinical trial study. The data were obtained from two st...